Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy

Vismodegib is approved for the treatment of adult patients with metastatic (mBCC) or locally advanced basal cell carcinoma (laBCC) that have recurred following surgery or for those who are not good candidates for surgery (risk/benefit ratio is against patient’s benefit, either because of the general...

Descripción completa

Detalles Bibliográficos
Autores principales: Apalla, Zoe, Papageorgiou, Chrysoula, Lallas, Aimilios, Sotiriou, Elena, Lazaridou, Elizabeth, Vakirlis, Efstratios, Kyrgidis, Athanassios, Ioannides, Demetrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436682/
https://www.ncbi.nlm.nih.gov/pubmed/28546761
http://dx.doi.org/10.2147/CCID.S101330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436682/
https://www.ncbi.nlm.nih.gov/pubmed/28546761
http://dx.doi.org/10.2147/CCID.S101330

Ejemplares similares